SCHEMBL6884435

SCHEMBL6884435

CCCN(CCC)c1c(N[C@@H](Cc2ccc(Nc3nc4ccccc4n3C)cc2)C(=O)OC)c(=O)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
ITGB1 P05556 7/20 0.42
ITGA4 P13612 7/20 0.42
DRD2 P14416 1/20 0.39
TBXA2R P21731 1/20 0.39
ELANE P08246 1/20 0.39
CRHR1 P34998 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888867 0.81 NPC1 (0.43) NPC1RAB9AITGB1ITGA4DRD2
SCHEMBL6888864 0.81 NPC1 (0.43) NPC1RAB9AITGB1ITGA4DRD2
SCHEMBL7715542 0.78 ITGB1 (0.41) ITGB1ITGA4ELANEMAPTKDM4E
SCHEMBL6887783 0.78 ELANE (0.42) NPC1RAB9AITGB1ITGA4DRD2
SCHEMBL7049320 0.77 NPC1 (0.39) NPC1RAB9AITGB1ITGA4DRD2
SCHEMBL7049316 0.77 NPC1 (0.39) NPC1RAB9AITGB1ITGA4DRD2
SCHEMBL7361897 0.73 ITGB1 (0.51) RAB9AITGB1ITGA4HSD17B10
SCHEMBL7361891 0.73 ITGB1 (0.51) RAB9AITGB1ITGA4HSD17B10
SCHEMBL7259001 0.72 ITGB1 (0.52) ITGB1ITGA4
SCHEMBL7105057 0.72 ITGB1 (0.52) ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6740654-B2 INHIBIT THE BINDING OF INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS, OR DISORDERS INVOLVING THE INAPPROPRIATE GROWTH OR MIGRATION OF CELLS. CELLTECH R & D LIMITED (GB) 2004-05-25 US disclosed
US-20020107263-A1 Squaric acid derivatives CELLTECH R&D, LTD. (GB) 2002-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107263-A1 Squaric acid derivatives SUCNR1, ICAM1, VCAM1 NPC1 1140/4885RAB9A 1901/4885ITGB1 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.